Pasar al contenido principal

INGENIERIA DE GANANCIA DE FUNCION DE PROTEINAS IN SILICO PARA NUEVAS APLICACIONES Y TERAPIAS

PID2021-125946OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Iridium-Catalyzed ortho-Selective Borylation of Aromatic Amides Enabled by 5-Trifluoromethylated Bipyridine Ligands

  • Marcos-Atanes, Daniel
  • Vidal Vides, Cristian
  • Navo Najera, Claudio Daniel
  • Peccati, Francesca
  • Jiménez Osés, Gonzalo
  • Mascareñas Cid, José Luis
Iridium-catalyzed borylations of aromatic C−H bonds are highly attractive transformations because of the diversification possibilities offered by the resulting boronates. These transformations are best carried out using bidentate bipyridine or phenanthroline ligands, and tend to be governed by steric factors, therefore resulting in the competitive functionalization of meta and/or para positions. We have now discovered that a subtle change in the bipyridine ligand, namely, the introduction of a CF3 substituent at position 5, enables a complete change of regioselectivity in the borylation of aromatic amides, allowing the synthesis of a wide variety of ortho-borylated derivatives. Importantly, thorough computational studies suggest that the exquisite regio- and chemoselectivity stems from unusual outer-sphere interactions between the amide group of the substrate and the CF3-substituted aryl ring of the bipyridine ligand
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Bis-CF3-bipyridine ligands for the Iridium-Catalyzed Borylation of N-Methylamides

  • Marcos-Atanes, Daniel
  • Jiménez-Osés, Gonzalo
  • Mascareñas Cid, José Luis
Bipyridine and phenanthroline are well-established neutral ligands for promoting iridium-catalyzed borylations of aromatic C–H bonds. However, their use with aliphatic substrates is almost uncharted. Herein we demonstrate that introducing CF substituents at the 5- and 5′-positions of bipyridine generates ligands that enable an efficient and regioselective iridium-catalyzed borylation of the methyl group in a broad variety of methylamides. The reaction shows broad functional group tolerance and exhibits remarkable selectivity, offering a powerful approach for the borylation of challenging aliphatic C–H bonds. Mechanistic investigations, including computational analysis, suggest that the accelerating effect of the ligand is likely associated with the formation of non-covalent dispersion interactions between the carbonyl amide of the substrates and the trifluoromethylated pyridine rings of the ligand.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplificationbased method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier
  • Sampedro-Torres-Quevedo, Cristina
  • Charco, Jorge M.
  • Díaz-Domínguez, Carlos M.
  • Peccati, Francesca
  • San-Juan-Ansoleaga, Maitena
  • Vidal, Enric
  • Gonçalves-Anjo, Nuno
  • Pérez-Castro, Miguel A.
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • Perez de Nanclares, Guiomar
  • Telling, Glenn
  • Geijo, Mariví
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrPC) into a pathogenic form (PrPSc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications., The authors would like to thank the following for their support: IKERBasque foundation, personnel from vivarium, IT service (in particular to Sara Gómez Ramos for her assistance with the PrPdex webpage), maintenance departments of CIC bioGUNE, Neiker and IRTA-CReSA. The authors would also like to acknowledge the work from past laboratory members of the Prion Research Lab from CIC bioGUNE, that despite not directly involved in the manuscript have contributed along the years to the development of all the methods and techniques currently used in the laboratory (specially to Tomás Barrio and Leire Hervá for their efforts at the initial and end stages of the work, respectively). Finally, we would like to thank Jesús R. Requena for always useful scientific discussions and advice. The present work was partially funded by different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010BC22, PID2021-125946OB-I00 and IJC2020-045506-I, funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021- 001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Effect of primary structural variation on cervid prion protein in flexibility, stability, and spontaneous misfolding propensity

  • Díaz-Domínguez, Carlos M.
  • Eraña, Hasier
  • Peccati, Francesca
  • Vidal, Enric
  • Charco, Jorge M.
  • Sampedro-Torres-Quevedo, Cristina
  • Pérez-Castro, Miguel A.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Telling, Glenn C.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Protein misfolding is central to numerous neurodegenerative disorders, collectively known as proteinopathies, which include Alzheimer's disease, Parkinson's disease, and prion diseases, among others. In many cases, specific polymorphisms of the proteins associated with these diseases influence their misfolding. However, the precise ways in which these polymorphisms affect protein integrity and how they contribute to misfolding propensity remain unclear. In the case of prion diseases, they are caused by prions or PrPSc, the misfolded isoforms of the cellular prion protein (PrPC). Chronic Wasting Disease (CWD) is a prion disease that affects cervids and can exhibit lymphotropic properties, making it the most widespread proteinopathy. For that reason, cervid PrPs and their polymorphisms have been extensively studied. To better understand the role of these polymorphisms, we analyzed 45 cervid PrP variants to assess their effects on flexibility, stability, and spontaneous misfolding propensity. The cervid variants were expressed as recombinant PrP in E. coli and were analyzed for thermal stability using circular dichroism. Additionally, the rec-PrPs served as substrates for Protein Misfolding Shaking Amplification (PMSA), enabling assessment of each variant's spontaneous misfolding propensity. This process led to the formation of bona fide prions, as confirmed by inoculation of one of the resulting conformers into transgenic mice expressing bank vole PrP. In parallel, molecular dynamics simulations were conducted to analyze the structural flexibility of the variants. While differences in protein flexibility were observed, no correlation was detected among flexibility, thermal stability, and the observed variable spontaneous misfolding propensity, suggesting that these properties are independent parameters., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22, and PID2020-117465GB-I00, funded by MCIN/AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). Also funded by MCIN/AEI /10.13039/501100011033, F.P. and G.J.O. were provided with the grants RYC2022-036457-I and PID2021-125946OB-I00, respectively. EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, as part of a grant from the European Joint Program for Neurodegenerative Research (JPND) JPND-2021-650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Synthesis and pharmacological characterization of a novel cannabinoid receptor 1 antagonist

  • Bengoetxea de Tena, Iker
  • Pereira Castelo, Gorka
  • Martínez Gardeazabal, Jonatan
  • Moreno Rodríguez, Marta
  • Manuel, Iván
  • Martínez Fernández, Claudio
  • Vaz Araújo, Belén
  • Gonzalez Ricarte, Javier
  • Álvarez Rodríguez, Maria Rosana
  • Torres Mozas, Angel
  • Peccati, Francesca
  • Jiménez Osés, Gonzalo
  • Rodríguez de Lera, Ángel
  • Rodríguez Puertas, Rafael
The endocannabinoid (eCB) system regulates several brain functions and is implicated in numerous conditions affecting the brain. Thus, the pharmacological blockade of cannabinoid receptors has a therapeutic potential but produces severe psychiatric side effects. Hence, new cannabinoid compounds with different pharmacological profiles are needed to potentially minimize this toxicity. The objective of this study, featuring original chemical insights, pharmacological analysis, and robust computational methods, was to synthesize and characterize a series of novel antagonists/inverse agonists of cannabinoid receptors. To do so, we first synthesized and then screened 11 novel compounds for affinity for cannabinoid receptors. After that, we characterized in depth the pharmacological profile of the most promising one, UVI3502, which showed affinity for two [3H]CP55,940 binding sites (IC50Hi 0.026 ± 0.43 nM and IC50Lo 772 ± 49.40 nM, R2 = 0.59) in the rat cortex. Binding assays performed in membranes overexpressing cannabinoid receptors 1 and 2 (CB1 and CB2) confirmed moderate affinity for both receptor subtypes, about 10-fold higher for the first one, indicating limited receptor subtype specificity. In key brain areas from the rodent brain, which have a much higher CB1 receptor density than CB2, the affinity of UVI3502 was further studied with neuroanatomical specificity by autoradiography. Functional [35S]GTPγS assays demonstrated that UVI3502 behaved as an antagonist of CB1 receptors, blocking the stimulation evoked by the potent cannabinoid receptor agonist CP55,940. The in silico characterization of the binding to the CB1 receptor through molecular docking and molecular dynamics suggests that this activity is explained by the planar and rigid structure of UVI3502, which is optimal for interactions with the inactive state of the receptor. Hence, we synthesized and characterized UVI3502 as a novel antagonist of CB1, making it a new pharmacological tool for the study of the eCB system and for blocking cannabinoid receptors in the central nervous system., Eusko Jaurlaritza | Ref. IT975-16, Eusko Jaurlaritza | Ref. IT1454-22, Instituto de Salud Carlos III | Ref. PI20/00153, Agencia Estatal de Investigación | Ref. PID2021-125946OB-I00, Agencia Estatal de Investigación | Ref. RYC2022-036457-I, Berrikuntza + Ikerketa + Osasuna Eusko Fundazioa | Ref. BIO22/ALZ/010, Euskal Herriko Unibertsitatea
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Pujana-Vaquerizo, Mikel
  • Martínez-Laosa, Belén
  • Ponce-Rodríguez, María
  • García-Longarte, Saioa
  • Mendizabal, Isabel
  • Gimeno, Ana
  • Rogalska, Malgorzata
  • Tan, Joycelyn
  • Cabrera, Diana
  • van Liempd, Sebastiaan
  • Ximenez-Embun, Pilar
  • Espinosa, Sergio
  • Fagoaga-Eugui, Maider
  • Peccati, Francesca
  • Zakrzewski, Maciej
  • Astobiza, Ianire
  • Arana-Castañares, Mikel
  • Cherkaoui, Sarah
  • Sendino, Maria
  • Martín-Barros, Inés
  • Ercilla, Amaia
  • Bozal-Basterra, Laura
  • Carlevaris, Onintza
  • Arruabarrena-Aristorena, Amaia
  • Pérez-Andrés, Encarnación
  • Santamaria-Zamorano, Telmo
  • Ferrer-Bonsoms, Juan A.
  • Carazo, Fernando
  • Ciesla, Maciej
  • Lobato, Cesar
  • Seoane, Joan
  • Martín-Martín, Natalia
  • Barrio, Rosa
  • Sutherland, James D.
  • Aransay, Ana M.
  • Falcón-Pérez, Juan Manuel
  • Martínez-Pastor, Barbara
  • Rubio, Angel
  • Blanco, Francisco J.
  • Hogarty, Michael D.
  • Morscher, Raphael J.
  • Berra, Edurne
  • Serwa, Remigiusz A.
  • Jiménez-Barbero, Jesús
  • Jiménez-Osés, Gonzalo
  • Efeyan, Alejo
  • Finley, Lydia
  • Lizcano, Jose M.
  • Muñoz, Javier
  • Valcarcel, Juan
  • Carracedo, Arkaitz
40 páginas, figuras y material suplementario., Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tertiary and quaternary structure remodeling by occupancy of the substrate binding pocket in a large glutamate dehydrogenase

  • Lázaro, Melisa
  • Chamorro, Nicolás
  • López-Alonso, Jorge P.
  • Charro, Diego
  • Rasia, Rodolfo M.
  • Jiménez-Osés, Gonzalo
  • Valle, Mikel
  • Lisa, María-Natalia
[Data Availability Statement] Cryo-EM maps obtained for mL-GDH180 were deposited in the Electron Microscopy Data Bank under the accession codes EMD-52419 (Open), EMD-52420 (Closed1), EMD-52421 (Closed2), EMD-52422 (empty-monomer), EMD-52423 (cofactor-monomer), EMD-52424 (cofactor/ligand-monomer), EMD-52425 (Open-cofactor/ligand-monomer), EMD-52426 (Closed1-cofactor/ligand-monomer), EMD-52427 (Closed2-cofactor/ligand-monomer), EMD-52428 (total-monomer) and EMD-52429 (Closed2-cofactor/ligand-tetramer). Atomic coordinates were deposited in the Protein Data Bank under the accession codes 9HUX (Open), 9HUY (Closed1), 9HUZ (Closed2), 9HV0 (empty-monomer), 9HV4 (cofactor-monomer), 9HV5 (cofactor/ligand-monomer) and 9HV6 (total-monomer)., Glutamate dehydrogenases (GDHs) catalyze the oxidative deamination of L-glutamate to 2-oxoglutarate using NAD(P)+ as a cofactor. The large type of GDHs (L-GDHs) displays a dynamic homotetrameric architecture that alternates between open and closed states. However, the catalytic mechanism and the functional relevance of the large conformational changes in L-GDHs remain poorly understood. Here, we use cryo-EM to investigate the structure and the conformational landscape of the mycobacterial L-GDH composed of 180 kDa subunits (mL-GDH180) when incubated with L-glutamate and NAD+. Classification of the heterogeneous population of tetramers reveals opening-closing motions and sorting of individual subunits resolves the occupancy of the cofactor and substrate binding pockets. Cryo-EM maps show that ligand binding to the glutamate binding pocket is accompanied by structural changes in a region approximately two nanometers away from the active site, leading to the formation of a previously undetected interaction between the catalytic domains of neighboring subunits in mL-GDH180 closed tetrameric states. Our findings indicate that the occupancy of the substrate binding site of mL-GDH180 is linked to a remodeling of both the tertiary and quaternary structure of the enzyme., This work was supported by grants PICT 2019-00989 and PICT 2021-00253 from the Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (Agencia I + D + i, Argentina) to MNL as well as grants PID2021-124074NB-I00 and PID2021-125946OB-I00 from Agencia Estatal de Investigación of Spain to MV and GJO, respectively. We also thank the Severo Ochoa Center of Excellence Accreditation CEX2021-001136-S. MNL and RMR are career investigators from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina). NC holds a CONICET PhD fellowship. Some of this work was performed at the Basque Resource for Electron Microscopy located at Instituto Biofisika (UPV/EHU, CSIC), supported by the Department of Science, Universities and Innovation and the Innovation Fund of the Basque Government, with additional support from MCIN (Recovery, Transformation and Resilience Plan) and the Basque Government “Biotechnology Complementary Plan Applied to Health” with funding from European Union NextGenerationEU (PRTR-C17.I1; PRTR-C17.I01.P01.S13) (AAAA_ACG_AY_2539/22_05)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effect of primary structural variation on cervid prion protein in flexibility, stability, and spontaneous misfolding propensity

  • Díaz-Domínguez, Carlos M.
  • Eraña, Hasier
  • Peccati, Francesca
  • Vidal, Enric
  • Charco, Jorge M.
  • Sampedro-Torres-Quevedo, Cristina
  • Pérez-Castro, Miguel A.
  • Lorenzo, Nuria L.
  • Giler, Samanta
  • Telling, Glenn C.
  • Geijo, Mariví
  • Requena, Jesús R.
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Protein misfolding is central to numerous neurodegenerative disorders, collectively known as proteinopathies, which include Alzheimer's disease, Parkinson's disease, and prion diseases, among others. In many cases, specific polymorphisms of the proteins associated with these diseases influence their misfolding. However, the precise ways in which these polymorphisms affect protein integrity and how they contribute to misfolding propensity remain unclear. In the case of prion diseases, they are caused by prions or PrPSc, the misfolded isoforms of the cellular prion protein (PrPC). Chronic Wasting Disease (CWD) is a prion disease that affects cervids and can exhibit lymphotropic properties, making it the most widespread proteinopathy. For that reason, cervid PrPs and their polymorphisms have been extensively studied. To better understand the role of these polymorphisms, we analyzed 45 cervid PrP variants to assess their effects on flexibility, stability, and spontaneous misfolding propensity. The cervid variants were expressed as recombinant PrP in E. coli and were analyzed for thermal stability using circular dichroism. Additionally, the rec-PrPs served as substrates for Protein Misfolding Shaking Amplification (PMSA), enabling assessment of each variant's spontaneous misfolding propensity. This process led to the formation of bona fide prions, as confirmed by inoculation of one of the resulting conformers into transgenic mice expressing bank vole PrP. In parallel, molecular dynamics simulations were conducted to analyze the structural flexibility of the variants. While differences in protein flexibility were observed, no correlation was detected among flexibility, thermal stability, and the observed variable spontaneous misfolding propensity, suggesting that these properties are independent parameters., The present work was partially funded by three different grants awarded by “Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22, and PID2020-117465GB-I00, funded by MCIN/AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF). Also funded by MCIN/AEI /10.13039/501100011033, F.P. and G.J.O. were provided with the grants RYC2022-036457-I and PID2021-125946OB-I00, respectively. EFA031/01 NEURO-COOP, which is co-funded at 65 % by the European Union through Programa Interreg VI-A España-Francia-Andorra (POCTEFA 2021-2027). Additional funding was provided by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, as part of a grant from the European Joint Program for Neurodegenerative Research (JPND) JPND-2021-650-130. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplificationbased method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier
  • Sampedro-Torres-Quevedo, Cristina
  • Charco, Jorge M.
  • Díaz-Domínguez, Carlos M.
  • Peccati, Francesca
  • San-Juan-Ansoleaga, Maitena
  • Vidal, Enric
  • Gonçalves-Anjo, Nuno
  • Pérez-Castro, Miguel A.
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu
  • Fernández-Muñoz, Eva
  • Perez de Nanclares, Guiomar
  • Telling, Glenn
  • Geijo, Mariví
  • Jiménez-Osés, Gonzalo
  • Castilla, Joaquín
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrPC) into a pathogenic form (PrPSc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications., The authors would like to thank the following for their support: IKERBasque foundation, personnel from vivarium, IT service (in particular to Sara Gómez Ramos for her assistance with the PrPdex webpage), maintenance departments of CIC bioGUNE, Neiker and IRTA-CReSA. The authors would also like to acknowledge the work from past laboratory members of the Prion Research Lab from CIC bioGUNE, that despite not directly involved in the manuscript have contributed along the years to the development of all the methods and techniques currently used in the laboratory (specially to Tomás Barrio and Leire Hervá for their efforts at the initial and end stages of the work, respectively). Finally, we would like to thank Jesús R. Requena for always useful scientific discussions and advice. The present work was partially funded by different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010BC22, PID2021-125946OB-I00 and IJC2020-045506-I, funded by MCIN/ AEI /10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024, to J.C. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021- 001136-S, also funded by MCIN/AEI /10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Protein Misfolding Shaking Amplification-based method for the spontaneous generation of hundreds of bona fide prions

  • Eraña, Hasier|||0000-0001-8776-4211
  • Sampedro-Torres-Quevedo, Cristina|||0000-0001-6374-1760
  • Charco, Jorge M.|||0000-0003-3476-1855
  • Díaz-Domínguez, Carlos M.|||0000-0002-0410-1963
  • Peccati, Francesca|||0000-0002-7813-8216
  • San-Juan-Ansoleaga, Maitena|||0000-0001-7968-510X
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • Gonçalves-Anjo, Nuno|||0000-0003-0586-2550
  • Pérez-Castro, Miguel A.|||0000-0003-2850-3470
  • González-Miranda, Ezequiel
  • Piñeiro, Patricia|||0000-0002-0062-2542
  • Fernández-Veiga, Leire
  • Galarza-Ahumada, Josu|||0000-0003-0275-559X
  • Fernández-Muñoz, Eva
  • Pérez de Nanclares, Guiomar|||0000-0002-2424-5294
  • Telling, Glenn
  • Geijo, Maria V.|||0000-0002-3120-1038
  • Jiménez-Osés, Gonzalo|||0000-0003-0105-4337
  • Castilla, Joaquín|||0000-0002-2216-1361
Prion diseases are a group of rapidly progressing neurodegenerative disorders caused by the misfolding of the endogenous prion protein (PrP C) into a pathogenic form (PrP Sc). This process, despite being the central event underlying these disorders, remains largely unknown at a molecular level, precluding the prediction of new potential outbreaks or interspecies transmission incidents. In this work, we present a method to generate bona fide recombinant prions de novo, allowing a comprehensive analysis of protein misfolding across a wide range of prion proteins from mammalian species. We study more than 380 different prion proteins from mammals and classify them according to their spontaneous misfolding propensity and their conformational variability. This study aims to address fundamental questions in the prion research field such as defining infectivity determinants, interspecies transmission barriers or the structural influence of specific amino acids and provide invaluable information for future diagnosis and therapy applications. To study neurodegenerative prion diseases, a method (PMSA) for generating prions spontaneously is presented. Applied to 380+ different prion proteins, their tendency to become pathogenic was ranked, illuminating their formation process.